Table 3.
Patient characteristics (Penn Cohort)
| n = 60 | |
|---|---|
| Age, yr | 50 ± 18 |
| Sex, female, % | 100 |
| Body mass index, kg/m2 | 28 ± 6.2 |
| Race, % | |
| White | 58 |
| African American | 32 |
| Other | 10 |
| PAH etiology, % | |
| Idiopathic/heritable | 50 |
| Connective tissue disease | 31 |
| Other | 19 |
| PAH medications, % | |
| Only oral | 56 |
| Inhaled ± oral | 9 |
| Parenteral prostacyclin analog ± oral | 35 |
| WHO functional class, % | |
| I | 9 |
| II | 46 |
| III | 45 |
| emPHasis-10 | 19 ± 12 |
| 6-minute walk distance, m | 403 ± 129 |
| TAPSE, cm | 2.0 (1.7–2.2) |
| Accelerometry variables (per day) | |
| Vector magnitude counts | 1,860,000 ± 613,800 |
| Step counts | 7,960 ± 2,710 |
| Sedentary, min | 333 (255–396) |
| Light activity, min | 236 (207–260) |
| Moderate activity, min | 16 (12–29) |
Definition of abbreviations: PAH = pulmonary arterial hypertension; Penn = Pennsylvania; TAPSE = tricuspid annular plane systolic excursion; WHO = World Health Organization.
Data are summarized as mean ± SD or median (interquartile range).